Our data demonstrate that tadalafil treatment provides additional therapeutic opportunities for the use of multiple PDE5 inhibitors in the treatment of peripheral neuropathy and possibly with less frequent administration than the short acting sildenafil. This evidence concerns the gene PDE5A and peripheral neuropathy.